^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

PIK3R1 mutation

i
Other names: PIK3R1, Phosphoinositide-3-Kinase Regulatory Subunit 1, Phosphatidylinositol 3-Kinase 85 KDa Regulatory Subunit Alpha, Phosphoinositide-3-Kinase, Regulatory Subunit 1 (Alpha), Phosphatidylinositol 3-Kinase Regulatory Subunit Alpha, Phosphoinositide-3-Kinase Regulatory Subunit Alpha, PtdIns-3-Kinase Regulatory Subunit Alpha, PI3K Regulatory Subunit Alpha, PI3-Kinase Subunit P85-Alpha, GRB1, Phosphatidylinositol 3-Kinase, Regulatory Subunit, Polypeptide 1 (P85 Alpha), Phosphatidylinositol 3-Kinase
Entrez ID:
Related biomarkers:
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
09/28/2022
Initiation :
08/27/2022
Primary completion :
10/29/2026
Completion :
10/29/2026
ER • PIK3CA • PGR • PTEN • PIK3R1 • PI3K
|
ER positive • PIK3CA mutation • PTEN deletion • PIK3R1 mutation
|
fulvestrant • Aliqopa (copanlisib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase N/A
Medical University of Vienna
Completed
Last update posted :
09/05/2022
Initiation :
05/01/2014
Primary completion :
12/31/2021
Completion :
12/31/2021
EGFR • BRAF • KRAS • TP53 • PIK3CA • NRAS • PTEN • FGFR2 • CDKN2A • ARID1A • AKT1 • KMT2D • FBXW7 • RNF43 • CTNNB1 • PIK3R1 • MLL2 • FAT3 • CSMD3
|
PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase N/A
Medical University of Vienna
Completed
Last update posted :
09/05/2022
Initiation :
05/01/2014
Primary completion :
12/31/2021
Completion :
12/31/2021
EGFR • BRAF • KRAS • TP53 • PIK3CA • NRAS • PTEN • FGFR2 • CDKN2A • ARID1A • AKT1 • KMT2D • FBXW7 • RNF43 • CTNNB1 • PIK3R1 • MLL2 • FAT3 • CSMD3
|
PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation
Phase 2
Peter MacCallum Cancer Centre, Australia
Completed
Last update posted :
08/16/2022
Initiation :
09/07/2015
Primary completion :
10/26/2021
Completion :
10/26/2021
EGFR • HER-2 • KRAS • ALK • ER • PIK3CA • NRAS • PGR • PTEN • HRAS • AKT1 • PIK3R1 • INPP4B • PI3K • PIK3R3
|
KRAS mutation • ER positive • EGFR mutation • PIK3CA mutation • HER-2 negative • EGFR amplification • ALK mutation • AKT1 mutation • PIK3R1 mutation
|
Piqray (alpelisib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
St. Joseph's Hospital and Medical Center, Phoenix
Active, not recruiting
Last update posted :
03/14/2022
Initiation :
12/21/2018
Primary completion :
06/30/2022
Completion :
07/31/2022
PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CDK4 • CDKN2B • PIK3R1 • PIK3C2B
|
PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • PIK3CA mutation + PTEN mutation • PIK3R1 mutation
|
everolimus • Kisqali (ribociclib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase N/A
Medical University of Vienna
Completed
Last update posted :
02/25/2020
Initiation :
02/01/2012
Primary completion :
11/01/2018
Completion :
11/01/2018
EGFR • BRAF • KRAS • TP53 • PIK3CA • NRAS • PTEN • FGFR2 • CDKN2A • ARID1A • AKT1 • KMT2D • FBXW7 • RNF43 • CTNNB1 • PIK3R1 • MLL2 • FAT3 • CSMD3
|
PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation
Phase 2
Patrick Y. Wen, MD
Completed
Last update posted :
03/19/2019
Initiation :
09/01/2011
Primary completion :
10/01/2016
Completion :
02/01/2019
PIK3CA • PTEN • PIK3R1
|
PIK3CA mutation • PTEN deletion • PTEN mutation • PIK3R1 mutation
|
buparlisib (AN2025)
Phase 1
Pathway Therapeutics, Inc.
Completed
Last update posted :
10/25/2012
Initiation :
06/01/2011
Primary completion :
08/01/2012
Completion :
09/01/2012
BRAF • KRAS • PIK3CA
|
KRAS mutation • BRAF mutation • PIK3CA mutation • PIK3R1 mutation
|
VCD-597